Acipimox sodium
Modify Date: 2024-01-16 13:32:14
Acipimox sodium structure
|
Common Name | Acipimox sodium | ||
|---|---|---|---|---|
| CAS Number | 76958-97-9 | Molecular Weight | 176.11 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C6H5N2NaO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Acipimox sodiumAcipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3]. |
| Name | Acipimox sodium |
|---|
| Description | Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Acipimox sodium (0-100 µM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner[2]. Acipimox sodium (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats[2]. |
| In Vivo | Acipimox sodium (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice[3]. Animal Model: Acipimox sodium (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice[3]. Dosage: 50 mg/kg Administration: Intraperitoneal injection Result: Reduced circulating levels of FFA and glucose after 3 h. |
| References |
| Molecular Formula | C6H5N2NaO3 |
|---|---|
| Molecular Weight | 176.11 |